Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Might move like rbz did friday
Looks like I might be wrong lol, we’ll see close to $3 already
I’m banking on a drop to $2.45 then $3.00+ later today, but what do I know?? Lol imo
Pretty big news actually. Low ss as well. But yeah, the first test comes here in about 16 minutes.
Looks like this is the pick of the day. Will fall back at open but should launch by mid AM
News: $FCSC Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors
- Annual NACD Directorship 100 List Recognizes the Most Influential Corporate Governance Experts - EXTON, Pa., April 03, 2019 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (Nasdaq: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and conn...
In case you are interested https://marketwirenews.com/news-releases/fibrocell-announces-board-member-christine-st-clare-honored-by-national-association-of-corporate-directors-7939286.html
With a little good news, the low volume of shares outstanding, and a few shorts in the mix this thing can be $10 in a few weeks Spread the word
Why I'd this board so dead like this?? So many crap penny stocks have HUGE followings!
News: $FCSC Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
- Company to provide update on Type B meeting with FDA on Phase 3 clinical trial design for FCX-007 gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB) - - Company to highlight updated data from ongoing FCX-007 Phase 1/2 clinical trial for ...
Read the whole news https://marketwirenews.com/news-releases/fibrocell-to-host-conference-call-webcast-for-full-year-2018-financial-results-and-recent-highlights-on-march-27-2019-7858192.html
Török vagyok
2.40 solid support. watch for 2.60 breakout
Burn the shorts. If they can’t sell this will fly
$60K exchanged hands at $2.32. most were dip buys.
2.32
3 day, 5 min chart. see all the green candles yesterday close and market open today
good times ahead if 2.37 breaks shortly
I NEVER posted to buy it @ 3.00 as you just stated today. Otterman you are blatantly confused there about me.
Posts here prove it all about me dating back to July 26 - August 15.
Anyone who followed me privately or here at this board clearly sees my posts scaling into $FCSC @ 2.15-2.20 (or less) late July & then after that @ 1.85-1.90 for an avg cost of 2.02.
Then August 15 posted exited at a slight profit after it had resistance in 2.30's.
These are facts with dated posts to back them up, not subjective opinions.
Done with this. G-Bye!
Decided to let go of this... FCSC was exited recently for a slight profit (or beak even for some) at my private email group.
In my view it seems to have lost steam after reversing from lows last week.
Before that we just sold another biotech ~ NV*X for a 20-35% profit around the 1.43-1.55 area between 8/09/18 - 8/13/18 after it was alerted privately Monday, August 6 @ 1.19 limit. Followers had 2 solid days or more to enter it low @ 1.19 before it flew upward after earnings... See my profile for more info & posting history
It moved higher into area I mentioned could be possible after my post August 10. Just a matter now if it holds recent area of support of at least 2+.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142836468
We'll see yet if it pops more or flops
$FCSC ~ Nice close for 8/10. It squeaked above prior resistance of 2.09 that was hanging over it for over a week to a new high for the day @ 2.10. If it can hold above latest price advancement, we could see 2.20's-2.50+ area or more yet for a short term trade.
-------------------------------------------------------------------------------
Basic indicators starting to shape up well such as MACD starting to set up well along with RSI.
It could soon prove to be a nice entry after the July 27 share offering (S-1) got priced into it, which I prospected about afterwards:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142555655
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142565079
$FCSC recovering nicely after earnings this morning when it tested lows.
Basic indicators starting to shape up well such as MACD starting to set up well along with RSI.
It could soon prove to be a nice entry after the July 27 share offering (S-1) got priced into it, which I prospected about afterwards:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142555655
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142565079
That was a relatively very positive earnings report this morning with multiple good updates in it, regardless of how the market may react yet going forward.
It decreased costs substantially & guided with plenty of cash thru 4th Qtr 2019 (after many recent share offerings).
$FCSC also updated well on clinical developments including an enrollment initiated just recently in August.
Fibrocell Science 2nd Qtr - 2018 Financial Results (8/09/18)
“Our FCX-013 gene therapy program for the treatment of moderate to severe localized scleroderma also made notable progress this quarter. The U.S. Food and Drug Administration (FDA) allowed our Investigational New Drug application earlier this year, and in August, we initiated the first investigator site for clinical enrollment for our open label, single arm Phase 1/2 clinical trial,”
It looks more stable the past couple days with MACD starting to converge bullish. Probably a buying opportunity since last week (based on the chart) like I said it likely could be right after that July 27 share offering got priced in.
It just needs to weather thru the earnings Aug 9, & we'll see what happens. Otherwise it is setting up nicely so far today.
Whatcha think now??
I always assess a company's finances & cash, especially biotech-pharma before I ever trade it. In fact I'm renowned for that as a major rule of criteria necessary before touching a stock like FCSC, & hence I am not solely dependent on technicals like a common blind sheep in the market.
But random anomalies can occur, & $FCSC pulled that on the public by doing another round of share offerings after having doing some recently already.
That said, I think this may be close to pricing in the July 27 filing.
We'll see
Thats why charting takes more than a few hour read to make a call like that.
It did another share offering filing 7/27 after they just did one in early July 7 after they did one I think not too long before that!
http://ih.advfn.com/p.php?pid=nmona&article=77954891
That's why it fell after July 26 when candlesticks were looking good
It's getting really oversold though, so I'd be looking soon for stability and potential entry point (for a short term trade)
It was 'Basing' as of yesterday from 2.13 prior support which had lasted about a week--- when I made the post.
It was on July 26 showing great signs with a nice green candlestick trading up toward 2.33 along with the standpoint of an entry under 2.20, so one can't fault me for pointing out that it looked like FCSC was in early stage of turning back upward yesterday.
Of course though after witnessing it break down some more today to 2.05 as the latest new low, one has to re-assess & wait to see yet what happens with an objective open mind.
In the short term this can still be close to being ready for a trade higher (despite a longer term down trend which is common for these types of stocks). Again, we'll wait and see what develops.
Below is a July 26 after market close quote from AmericanBulls.com which substantiates the premise I made July 26 as a reasonable speculation.
I made my post hours before their website later in the evening updated to post below the Buy signal generated from their computerized candlestick analysis.
Also note that I'm only using them below as an example to support what I stated regarding technicals as a reasonable assertion on July 26 & that I'm not abdicating that the website below is the ultimate barometer to follow in general or anything.
----------------------------------------------------------------------------
$FCSC {Quoted from AmericanBulls.com}:
Signal Update:
July 26, 2018
Our system’s recommendation today is to BUY. The BULLISH HARAMI CROSS pattern finally received a confirmation because the prices crossed above the confirmation level which was at 2.2050, and our valid average buying price stands now at 2.2100.
Last Pattern:BULLISH HARAMI CROSS
Pattern Description This is a major bullish reversal pattern, which is even more significant than a regular Bullish Harami. The outline again looks like a pregnant woman, as with the Bullish Harami Pattern.
Sure would love to see that base youre talking about. Vhart shows straight down but for a few hiccups. No base in site yet.
$FCSC ~ Appears to be starting a nice gap upward since this morning from 2.15 & coming from the recent support level of 2.13 established since last week.
It seems it was a nice low floater type of opportunity (with a decent combination of liquidity, too) that was available for entry under 2.20 earlier this morning.
We'll see where it goes yet & if it is setting up for a break out higher. Speculatively at an early stage yet, it certainly seems poised for a reversal & a break out higher.
So far in 2.30's this afternoon today.
is this company under the umbrella of intrexon?...tia
If someone came in and purchased 1mil shares of this stock it’ll go to $10. 10% short on 5mil outstanding. Blow those shorts up. Talk about an opportunity of s lifetime Maybe $20. If they panic
If someone came in and purchased 1mil shares of this stock it’ll go to $10. 10% short on 5mil outstanding. Blow those shorts up. Talk about an opportunity of s lifetime Maybe $20. If they panic
Im DONE with this POS SELL
SOLD ALL MY SHARES - TIME TO MOVE ON
PUMP IS OVER
Holding all shares...still
* * $FCSC Video Chart 06-21-18 * *
Link to Video - click here to watch the technical chart video
Shares Outstanding Just 7,7OO,OOO
https://www.nasdaq.com/symbol/fcsc/stock-report
Great Day...Holding over night
Fibrocell Announces Review of Strategic Alternatives
http://ir.fibrocellscience.com/phoenix.zhtml?c=253777&p=irol-newsArticle&ID=2343185
Followers
|
105
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
7054
|
Created
|
01/09/08
|
Type
|
Free
|
Moderators |
Fibrocell Science, Inc. is a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications.
Welcome to the new Fibrocell Science, Inc. and our new web site. I am pleased to have this opportunity to share my enthusiasm with you as Fibrocell’s Chairman of the Board of Directors.
We have been extremely busy charting the course for Fibrocell as a biotechnology company focused on the power of regenerative fibroblast cells for aesthetic, medical and scientific applications.
We have a challenging and exciting path before us as we continue to prepare for the U.S. Food & Drug Administration response to the biologics license application (BLA) we submitted in March 2009 for the use of Laviv™ (azficel-T)*, Fibrocell Science’s lead therapy, for the treatment of moderate to severe nasolabial fold wrinkles. The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee, which reviewed our therapy on October 9, 2009, voted 11 yes to 3 no that the data presented demonstrated efficacy, and 6 yes to 8 no that the data demonstrated safety, both for the proposed indication.
We are pleased to begin operations under Fibrocell Science, Inc., having reorganized the former Isolagen, Inc. and significantly reduced the company’s debt from US $81M to US $6M. We now look forward to an ambitious evaluation of our clinical priorities to maximize the potential use of our therapy in additional indications such as full-face rejuvenation, acne scars, burn scars and dental applications.
We have considerable work before us at Fibrocell Science, and we welcome the challenge. I join Fibrocell with extensive commercial experience from GlaxoSmithKline, where I most recently served as senior vice president, Pharmaceuticals and Vaccines. I am proud to have a strong management team helping guide this new company, including Declan Daly, former Isolagen chief executive officer, who was instrumental in our reorganization and remains committed to the company’s success.
Thank you for your interest in the new Fibrocell Science, Inc.
Sincerely,
David Pernock
Chairman
Fibrocell Science, Inc.
Fibrocell Therapy is an investigational autologous cell therapy. In the Fibrocell Science patented process, a patient’s own natural fibroblasts are extracted, multiplied and re-injected as personalized therapy. Fibroblasts are cells that contribute to the formation of connective tissue fibers. These matrix fibers are critical to the strength and elasticity of the skin.
Broadly, the regenerative effects of fibroblasts include:
- The ability to synthesize the extracellular matrix components and, thus, to improve skin texture,
- The secretion of matrix fibers, including collagen, and
- Playing a critical role in wound healing and tissue repair.
The Company prepares the Fibrocell Therapy through a streamlined process that begins with removing a small sample of cells from behind a patient’s ear and sending that sample to the Fibrocell cGMP facility. The process expands fibroblasts into tens of millions of new cells, which are then formulated into an autologous cellular therapy. Cells are frozen and used for multiple treatment sessions. The therapy is reintroduced into the patient’s skin by injection, which we believe results in an increase in the local fibroblast population, collagen formation and assists the body’s own regenerative healing process. In controlled clinical studies, a significant improvement in the appearance of nasolabial fold wrinkles was observed after injecting Fibrocell Therapy.
Regenerative fibroblast cells may have potential in use for broad aesthetic, medical and scientific applications. The Fibrocell Therapy for aesthetics, azficel-T, proposed brand name Laviv™, is currently under review by the FDA for the treatment of moderate to severe nasolabial fold wrinkles. Fibrocell Science, Inc. is planning to continue studies for additional aesthetic and therapeutic indications for azficel-T.
The company manufactures its cell therapy at a cGMP manufacturing facility in Pennsylvania.
Fibroblasts are cells that contribute to the formation of connective tissue fibers. Fibrocell's future scientific focus will be on regenerative medicine that leverages the direct and indirect therapeutic benefit of fibroblasts.
Fibrocell has submitted a biologics license application to the U.S. Food & Drug Administration (FDA) based on its Phase III clinical trials evaluating the efficacy and safety of its azficel-T in treating moderate to severe nasolabial fold wrinkles in patients older than 18 year of age.
In addition to wrinkle correction, Fibrocell has obtained statistically significant results in a Phase II/III acne scar clinical trial and a Phase II open label full face rejuvenation study. Fibrocell also has results in early burn scars and periodontal disease studies.
Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence.
Fibrocell Therapy is an investigational autologous cell therapy. In the Fibrocell Science patented process, a patient's own natural fibroblasts are extracted, multiplied and re-injected as personalized therapy to regenerate skin. Fibroblasts are cells that contribute to the formation of connective tissue fibers. The Fibrocell Therapy for aesthetics, azficel-T, proposed brand name Laviv™ is currently under review by the FDA for the treatment of moderate to severe nasolabial fold wrinkles.
Fibrocell Science, Inc. is planning to continue studies for additional aesthetic and therapeutic indications for its Fibrocell Therapy, which is manufactured at a cGMP cell therapy manufacturing facility at its headquarters in Pennsylvania.
OCTOBER 09, 2009
Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
OCTOBER 06, 2009
Isolagen, Inc. Reorganizes as Fibrocell Science, Inc.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |